MedTrace Logo

Ruxolitinib and Methylprednisolone as a First-line Treatment for Macrophage Activation Syndrome

NCT05137496 · Status: UNKNOWN · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2022-03-17

No results posted yet for this study

Summary

The present study was a single-center, prospective, non-comparative in which macrophage activation syndrome patients were selected as the main subjects to evaluate the effect and safety of Ruxolitinib and methylprednisolone regimens as the first-line therapy .

Conditions

  • Macrophage Activation Syndrome

Interventions

DRUG

Ruxolitinib

0.3mg/kg/d, iv.gtt, for at least 2 weeks

DRUG

methylprednisolone

2mg/kg, d1-d5, gradually reduced, for at least 2 weeks

Sponsors & Collaborators

  • Beijing Friendship Hospital

    lead OTHER

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
1 Year
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-06-01
Primary Completion
2023-06-01
Completion
2024-06-01

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05137496 on ClinicalTrials.gov